Dementia with Lewy Bodies

ABSTRACT

Synucleinopathies, with and without dementia, encompass a wide range of diseases including Parkinson's disease, multiple system atrophy, rapid eye movement (REM) sleep behavior disorder, and dementia with Lewy bodies (DLB). DLB is a neurodegenerative disorder resulting in slowly progressive and unrelenting dementia until death. Prevalence studies suggest that it is the second most common dementing illness in the elderly. The neuropathologic findings of DLB show a wide anatomic range. Lewy bodies and Lewy-related pathology are found from the brain stem to the cortex and, in many cases, associated with concurrent Alzheimer's disease pathology. A recent international consortium on DLB has resulted in revised criteria for the clinical and pathological diagnosis of DLB incorporating new information about the core clinical features and improved methods for their assessment. The presentation of DLB is typically one of cortical and subcortical cognitive impairments, with worse visuospatial and executive dysfunction than Alzheimer's disease. There may be relative sparing of memory especially in the early stages. Core clinical features of DLB include fluctuating attention, recurrent visual hallucinations, and parkinsonism. Suggestive features include REM sleep behavior disorder, severe neuroleptic sensitivity, and low dopamine transporter uptake in the basal ganglia on functional neuroimaging. Additional supportive features that commonly occur in DLB, but with lower specificity, include repeated falls and syncope, transient, unexplained loss of consciousness, severe autonomic dysfunction, hallucinations in other modalities, systematized delusions, depression, relative preservation of medial temporal lobe structures on structural neuroimaging, reduced occipital activity on functional neuroimaging, prominent slow wave activity on electroencephalogram, and low uptake myocardial scintigraphy. Management of DLB includes pharmacological and nonpharmacological interventions for its cognitive, neuropsychiatric, motor, and sleep disturbances.

KEYWORDS

Dementia with Lewy bodies - Lewy body variant - dementia - α-synuclein

REFERENCES

• 1 Hansen L A, Samuel W. Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies.  Neurology. 1997;  48 126-132
• 2 Lewy F H. Handbuch der Neurologie. Berlin; Springer 1912
• 3 Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree-a new disease?.  Clin Neuropathol. 1984;  3 185-192
• 4 Polymeropoulos M H, Lavedan C, Leroy E et al.. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.  Science. 1997;  276 2045-2047
• 5 Spillantini M G, Schmidt M L, Lee V M, Trojanowski J Q, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies.  Nature. 1997;  388 839-840
• 6 Dawson T M, Dawson V L. Molecular pathways of neurodegeneration in Parkinson's disease.  Science. 2003;  302 819-822
• 7 Galvin J E, Lee V M, Trojanowski J Q. Synucleinopathies: clinical and pathological implications.  Arch Neurol. 2001;  58 186-190
• 8 Kotzbauer P T, Trojanowsk J Q, Lee V M. Lewy body pathology in Alzheimer's disease.  J Mol Neurosci. 2001;  17 225-232
• 9 Minoshima S, Foster N L, Petrie E C, Albin R L, Frey K A, Kuhl D E. Neuroimaging in dementia with Lewy bodies: metabolism, neurochemistry, and morphology.  J Geriatr Psychiatry Neurol. 2002;  15 200-209
• 10 Colosimo C, Hughes A J, Kilford L, Lees A J. Lewy body cortical involvement may not always predict dementia in Parkinson's disease.  J Neurol Neurosurg Psychiatry. 2003;  74 852-856
• 11 Merdes A R, Hansen L A, Jeste D V et al.. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies.  Neurology. 2003;  60 1586-1590
• 12 McKeith I G, Dickson D W, Lowe J et al.. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.  Neurology. 2005;  65 1863-1872
• 13 Lauterbach E C. The neuropsychiatry of Parkinson's disease.  Minerva Med. 2005;  96 155-173
• 14 Hurtig H I, Trojanowski J Q, Galvin J et al.. Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.  Neurology. 2000;  54 1916-1921
• 15 Aarsland D, Perry R, Brown A, Larsen J P, Ballard C. Neuropathology of dementia in Parkinson's disease: a prospective, community-based study.  Ann Neurol. 2005;  58 773-776
• 16 McKeith I G, Galasko D, Kosaka K et al.. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop.  Neurology. 1996;  47 1113-1124
• 17 McKeith I G, Ballard C G, Perry R H et al.. Prospective validation of consensus criteria for the diagnosis of dementia with Lewy bodies.  Neurology. 2000;  54 1050-1058
• 18 Collerton D, Burn D, McKeith I, O'Brien J. Systematic review and meta-analysis show that dementia with Lewy bodies is a visual-perceptual and attentional-executive dementia.  Dement Geriatr Cogn Disord. 2003;  16 229-237
• 19 Tiraboschi P, Salmon D P, Hansen L A, Hofstetter R C, Thal L J, Corey-Bloom J. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?.  Brain. 2006;  129 729-735
• 20 Briel R C, McKeith I G, Barker W A et al.. EEG findings in dementia with Lewy bodies and Alzheimer's disease.  J Neurol Neurosurg Psychiatry. 1999;  66 401-403
• 21 Ferman T J, Smith G E, Boeve B F et al.. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging.  Neurology. 2004;  62 181-187
• 22 Harding A J, Broe G A, Halliday G M. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe.  Brain. 2002;  125 391-403
• 23 McKeith I G, Wesnes K A, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies.  Dement Geriatr Cogn Disord. 2004;  18 94-100
• 24 Molloy S, McKeith I G, O'Brien J T, Burn D J. The role of levodopa in the management of dementia with Lewy bodies.  J Neurol Neurosurg Psychiatry. 2005;  76 1200-1203
• 25 McKeith I G, Perry R H, Fairbairn A F, Jabeen S, Perry E K. Operational criteria for senile dementia of Lewy body type (SDLT).  Psychol Med. 1992;  22 911-922
• 26 Walker Z, Costa D C, Walker R W et al.. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison.  Neurology. 2004;  62 1568-1572
• 27 Taki J, Yoshita M, Yamada M, Tonami N. Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease.  Ann Nucl Med. 2004;  18 453-461
• 28 Litvan I, MacIntyre A, Goetz C G et al.. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study.  Arch Neurol. 1998;  55 969-978
• 29 Galasko D. Cerebrospinal fluid biomarkers in Alzheimer disease: a fractional improvement?.  Arch Neurol. 2003;  60 1195-1196
• 30 Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.  Curr Med Res Opin. 2006;  22 49-59
• 31 Molloy S, McKeith I G, O'Brien J T, Burn D J. The role of levodopa in the management of dementia with Lewy bodies.  J Neurol Neurosurg Psychiatry. 2005;  76 1200-1203
• 32 Aarsland D, Mosimann U P, McKeith I G. Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies.  J Geriatr Psychiatry Neurol. 2004;  17 164-171